Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XMYPL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DB-1311
|
|||||
| Synonyms |
DB1311; DB 1311
Click to Show/Hide
|
|||||
| Organization |
Duality Biologics; BioNTech SE
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Proprietary DNA topoisomerase I inhibitor
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Duality Immune Toxin Antibody Conjugates (DITAC) platform.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.